Weight-loss and diabetes drugs drive Eli Lilly’s latest earnings beat
Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and revenue.
Unlock full access. Create a free account or sign in to continue.